Clinical significance of ErbB receptor family in urothelial carcinoma of the bladder: A systematic review and meta-analysis

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

The prognostic importance of examining ErbB receptor family expression in human bladder cancer remains uncertain. Using published evidence, we examined the clinical value and the updated results of clinical trials targeting ErbB receptor family members. Twenty-seven articles from 65 references related to ErbB receptor expression assessment in bladder cancer were reviewed. The estimates included the association significance, hazard ratios, and 95 confidence intervals (CIs) from actuarial curves and survival analyses. A meta-analysis was done on those reports using univariate log-rank tests or a Cox-regression model. The methods of analysis and study subjects chosen varied widely among studies. The overall risks of disease progression for patients with EGFR or ErbB2 overexpression were 4.5 (95 CI: 2.58.4) and 1.1 (95 CI: 0.61.9), and the risks of mortality were 3.0 (95 CI: 1.65.9) and 1.1 (95 CI: 1.01.2), respectively. However, the significance of coexpression patterns of the ErbB receptor family remains controversial. None of six clinical trials yielded convincing results for blockading ErbB receptor signaling in urothelial carcinoma. The results of this analysis suggest that assessing co-expression patterns of the ErbB family may provide better prognostic information for bladder cancer patients.

Original languageEnglish
Article number181964
JournalAdvances in Urology
DOIs
Publication statusPublished - 2012 Oct 8

Fingerprint

Meta-Analysis
Urinary Bladder
Confidence Intervals
Carcinoma
Urinary Bladder Neoplasms
Actuarial Analysis
Clinical Trials
Survival Analysis
Proportional Hazards Models
Disease Progression
ErbB Receptors
Mortality

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynaecology
  • Urology

Cite this

@article{7fbf2e0e4beb47c9954656a7b070f21f,
title = "Clinical significance of ErbB receptor family in urothelial carcinoma of the bladder: A systematic review and meta-analysis",
abstract = "The prognostic importance of examining ErbB receptor family expression in human bladder cancer remains uncertain. Using published evidence, we examined the clinical value and the updated results of clinical trials targeting ErbB receptor family members. Twenty-seven articles from 65 references related to ErbB receptor expression assessment in bladder cancer were reviewed. The estimates included the association significance, hazard ratios, and 95 confidence intervals (CIs) from actuarial curves and survival analyses. A meta-analysis was done on those reports using univariate log-rank tests or a Cox-regression model. The methods of analysis and study subjects chosen varied widely among studies. The overall risks of disease progression for patients with EGFR or ErbB2 overexpression were 4.5 (95 CI: 2.58.4) and 1.1 (95 CI: 0.61.9), and the risks of mortality were 3.0 (95 CI: 1.65.9) and 1.1 (95 CI: 1.01.2), respectively. However, the significance of coexpression patterns of the ErbB receptor family remains controversial. None of six clinical trials yielded convincing results for blockading ErbB receptor signaling in urothelial carcinoma. The results of this analysis suggest that assessing co-expression patterns of the ErbB family may provide better prognostic information for bladder cancer patients.",
author = "Tsai, {Yuh Shyan} and Cheng, {Hong Lin} and Tzai, {Tzong Shin} and Chow, {Nan Haw}",
year = "2012",
month = "10",
day = "8",
doi = "10.1155/2012/181964",
language = "English",
journal = "Advances in Urology",
issn = "1687-6369",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Clinical significance of ErbB receptor family in urothelial carcinoma of the bladder

T2 - A systematic review and meta-analysis

AU - Tsai, Yuh Shyan

AU - Cheng, Hong Lin

AU - Tzai, Tzong Shin

AU - Chow, Nan Haw

PY - 2012/10/8

Y1 - 2012/10/8

N2 - The prognostic importance of examining ErbB receptor family expression in human bladder cancer remains uncertain. Using published evidence, we examined the clinical value and the updated results of clinical trials targeting ErbB receptor family members. Twenty-seven articles from 65 references related to ErbB receptor expression assessment in bladder cancer were reviewed. The estimates included the association significance, hazard ratios, and 95 confidence intervals (CIs) from actuarial curves and survival analyses. A meta-analysis was done on those reports using univariate log-rank tests or a Cox-regression model. The methods of analysis and study subjects chosen varied widely among studies. The overall risks of disease progression for patients with EGFR or ErbB2 overexpression were 4.5 (95 CI: 2.58.4) and 1.1 (95 CI: 0.61.9), and the risks of mortality were 3.0 (95 CI: 1.65.9) and 1.1 (95 CI: 1.01.2), respectively. However, the significance of coexpression patterns of the ErbB receptor family remains controversial. None of six clinical trials yielded convincing results for blockading ErbB receptor signaling in urothelial carcinoma. The results of this analysis suggest that assessing co-expression patterns of the ErbB family may provide better prognostic information for bladder cancer patients.

AB - The prognostic importance of examining ErbB receptor family expression in human bladder cancer remains uncertain. Using published evidence, we examined the clinical value and the updated results of clinical trials targeting ErbB receptor family members. Twenty-seven articles from 65 references related to ErbB receptor expression assessment in bladder cancer were reviewed. The estimates included the association significance, hazard ratios, and 95 confidence intervals (CIs) from actuarial curves and survival analyses. A meta-analysis was done on those reports using univariate log-rank tests or a Cox-regression model. The methods of analysis and study subjects chosen varied widely among studies. The overall risks of disease progression for patients with EGFR or ErbB2 overexpression were 4.5 (95 CI: 2.58.4) and 1.1 (95 CI: 0.61.9), and the risks of mortality were 3.0 (95 CI: 1.65.9) and 1.1 (95 CI: 1.01.2), respectively. However, the significance of coexpression patterns of the ErbB receptor family remains controversial. None of six clinical trials yielded convincing results for blockading ErbB receptor signaling in urothelial carcinoma. The results of this analysis suggest that assessing co-expression patterns of the ErbB family may provide better prognostic information for bladder cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84866983438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866983438&partnerID=8YFLogxK

U2 - 10.1155/2012/181964

DO - 10.1155/2012/181964

M3 - Review article

AN - SCOPUS:84866983438

JO - Advances in Urology

JF - Advances in Urology

SN - 1687-6369

M1 - 181964

ER -